Perspective discusses how aging influences immune checkpoint inhibitors efficacy in cancer therapy, suggesting biomarkers for better strategies.
Key Points
Aging significantly reduces T-cell function, compromising antitumor immunity and limiting the benefits of immune checkpoint inhibitors.
The presence of senescent tumor cells releases pro-inflammatory cytokines, disrupting the tumor microenvironment and downregulating effective immune responses.
Age-related immune dysregulation leads to cellular exhaustion and abnormal biomarker expression, affecting immune checkpoint inhibitors efficacy.
Understanding these factors is crucial for enhancing immunotherapy effectiveness and personalizing cancer treatment for elderly patients.